Objective: Idiopathic chronic eosinophilic pneumonia (ICEP) is a rare eosinophilic lung disorder with an unknown etiology and is characterized by subacute or chronic respiratory and general symptoms, alveolar and/or peripheral eosinophilia, and the accumulation of eosinophils in the lungs. We aimed to present diagnostic test results and follow-up outcomes of 17 patients who were diagnosed with ICEP in our hospital in light of literature.
INTRODUCTION
Idiopathic chronic eosinophilic pneumonia (ICEP) is a rare eosinophilic lung disorder with an unknown etiology. It is characterized by peripheral eosinophilia and the accumulation of eosinophils in the lungs (1) . The disorder was first described in 1960 by Christoforis and Molnar, and the study with the first large series of patients was published by Carrington in 1969 (2) .
Its prevalence is unknown. ICEP is the most common cause of eosinophilic lung disorders in countries with a low rate of parasitic infections such as Europe and North America. It represents 3% of interstitial lung diseases in studies of large series (3) . The diagnosis of ICEP is made by characteristic imaging findings of alveolar eosinophilia and/or peripheral eosinophilia after the exclusion of other potential causes (4) . There is no standard dose and duration of corticosteroid therapy for treating ICEP. The initiation of therapy produces a dramatic improvement in symptoms within 24-48 h (5) . We aimed to present diagnostic test results and follow-up outcomes of 17 patients who were diagnosed with ICEP in our hospital in light of the literature.
METHODS

Patients and Data
A retrospective cohort study was performed between 2008 and 2013 at the Süreyyapaşa Chest Diseases and Thoracic Surgery Training and Research Hospital. The patient files were reviewed, and 17 patients diagnosed with ICEP were included.
The patients were evaluated with respect to age, gender, presenting complaints, presence of any comorbid disease, smoking status, and laboratory and radiological findings. Complaints of cough, shortness of breath, fever, sputum, and weight loss were considered as presenting complaints. A patient had smoked cigarettes at least for 1 year to have been considered as smoker.
The peripheral blood eosinophil count, erythrocyte sedimentation rate (ESR), serum total IgE level, serum C-reactive protein (CRP) level, and eosinophils in bronchoalveolar lavage (BAL) were recorded during the diagnostic stage and throughout the clinical follow-up. The serum CRP and total IgE levels of the patients were evaluated by a nephelometric assay using a BN Prospec device of Dade Behring Corporation (İstanbul, Turkey). Hemogram values were evaluated using a Coulter STKS hematological analyzer (Beckman Coulter Cooperation, Miami, FL, USA).
The results of the posterior-anterior (PA) chest X-ray and high-resolution thoracic computed tomography (CT) (Somatom Emotion; Siemens, Erlangen, Germany) during clinical follow-up and spirometric examinations (Spirolab III, MIR, Roma, Italy) at the presentation of the patients were recorded. 
Statistical Analysis
The patients' data were collected from hospital files and the hospital operating system. Data without a normal and homogeneous distribution were shown as median (min-max) values as well as numbers and percentages. For statistical analyses, Statistical Package for Social Sciences for Windows 22.0 (SPSS IBM Statistics New York, Armonk, USA) was used. The results were analyzed with a confidence level of 95% and a significance level of p<0.05.
Diagnostic Criteria
The diagnosis of ICEP was based on the presence of respiratory symptoms for usually more than 2 weeks, alveolar and/or blood eosinophilia (alveolar eosinophilia ≥40% at BAL differential cell count and blood eosinophilia ≥1000/mm 3 ), the presence of pulmonary infiltrates often with a peripheral predominance on chest imaging, and exclusion of any known cause of eosinophilic lung disease (Table 1 ) (4).
RESULTS
Patients and Clinical Data
The median age of the 17 patients was 35 years (range, 21-71 years); 9 (53%) were males and 8 (47%) were females. At presentation, 4 (23.5%) patients were on treatment for asthma and 4 (23.5%) were on treatment for allergic rhinitis. Seven (41.1%) patients had a history of smoking. The most common presenting symptoms were cough and shortness of breath (Table 2) .
Laboratory Findings
All patients had an increased eosinophil count and increased ESR at the baseline. The serum CRP level was higher in 14 of 16 patients with available measurements. Two patients had hypoxic respiratory failure that did not require intensive care. Pearson correlation was performed to examine the correlation between the blood eosinophil count and BAL eosinophil percentage. The blood eosinophil count did not correlate with the BAL eosinophil percentage (r=−0.173, p=0.508) (Figure 1 ).
Radiological Findings and Pulmonary Function Tests
The baseline posterior-anterior chest X-ray images of the patients showed pulmonary infiltrates with peripheral upper and middle zone predominance ( Figure 2 ). The thoracic CT images showed non-homogeneous increases in density, mostly involving the upper lobe and periphery ( Figures 3, 4) . The baseline pulmonary function tests (PFTs) showed obstructive type in 3 (18%), normal type in 3 (18%), and restrictive type of the disease in 11 (64%) patients; there was a reduction in the diffusing capacity of the lungs for carbon monoxide (DLCO) test in 7 (41%) patients, while 10 (59%) patients had normal DLCO results.
Diagnostic Method
The diagnosis of ICEP was made based on the patients' dramatic responses to treatment with steroids after the exclusion of other causes after the determination of eosinophils in the BAL fluid and/or peripheral blood. The percentage of eosinophils in the BAL fluid ranged from Table 3 .
Treatment and Clinical Follow-up
Following the diagnosis of ICEP, there was a remarkable improvement in the infiltrates on chest imaging and in presenting symptoms within 1 week after the initiation of systemic steroids ( Figure 5 ).
Recurrence occurred at months 4 and 6 during the clinical follow-up in 2 patients whose treatment was completed and in 7 patients while reducing the dose of steroids. Of these 9 patients with recurrence, 7 (77.7%) had a total IgE level of above 500/IU/mL. No recurrence was observed in 8 patients during treatment and follow-up, with a treatment duration of 12-18 months. Six patients with recurrence were maintained on a lower dose of steroids (methylprednisolone, 4-8 mg). The treatment and follow-up results of the patients are summarized in Table 4 .
DISCUSSION
In clinical practice, ICEP is included in idiopathic eosinophilic pneumonias in the classification of eosinophilic pneumonias (4) . Although it may occur in any age group, the mean age at diagnosis is 45 years, and it affects twice as many women as men (6, 7) . While two-thirds of patients have prior asthma at presentation, approximately 50% may also have a history of atopy, drug allergy, nasal polyposis, and urticaria (6) (7) (8) . Our patients had a mean age of 40.8 years at presentation, and the female/male ratio was 0.8. At baseline, 23.5% of our patients had a history of asthma and 23.5% had allergic rhinitis, which was lower than the rates in the literature.
The onset of symptoms is progressive and subacute. There are a few weeks or a month between the onset of symptoms and diagnosis in ICEP. In total, 60-90% of patients have a moderate shortness of breath, and the most common cause is cough in 90% of the patients. While 20% of the patients have rhinitis and sinusitis, chest pain and hemoptysis are rare symptoms. Other than common respiratory symptoms, systemic symptoms, such as weight loss, anorexia, and fatigue, may also occur (6, 7).
In our patients, the most common symptoms included cough (94%), shortness of breath (76%), and high fever (35%). Respiratory failure requiring mechanical ventilation is rare compared to idiopathic acute eosinophilic pneumonia (9) . Two of our patients had hypoxic respiratory failure that did not require mechanical ventilator support. Many patients who have not received systemic treatment with steroids have increased levels of peripheral blood eosinophilia, which is the most important key to the diagnosis. In studies with large series, the presence of peripheral blood eosinophilia (representing 20-30% of blood leukocytes) and BAL eosinophilia (more than 25% eosinophils at the BAL cell count) have been considered to be major criteria (4, 6, 7) .Although non-specific, increased serum CRP levels and ESRs may also occur. Total IgE levels may be elevated in approximately 50% of the patients (6, 7). In our study, the average concentration of eosinophils in the peripheral blood was 6160/mm 3 (1300-14940/mm 3 ), with percentages of eosinophils ranging from 17 to 67.7. The BAL eosinophil percentages of our patients ranged from 3 to 80. Among those 14 patients whose total IgE level was measured, only 2 had a normal total IgE level, which was, in fact, higher compared to that in the literature. Furthermore, ESRs were higher in all our patients, while serum CRP levels were within the normal range in only 2 patients.
On chest imaging, ICEP is characterized by bilateral alveolar infiltrates of a migratory, temporary, patchy pattern in the periphery (2, 6, 7) . Thoracic CT reveals opacities, mostly bilateral with upper lobe predominance (10) (11) (12) . Peripheral symmetrical alveolar lesions, defined as the "photographic negative" of pulmonary edema, occur in 25% of the patients, and they are diagnostic of ICEP (13, 14) . Pleural effusions are present in 10% of the patients, while cavitary lesions, nodular infiltrations, and atelectasis are among the rare radiologic findings (7, 12, 15) . Our patients showed non-homogeneous bilateral patchy alveolar infiltrates in the periphery with upper and mid zone predominance, which is consistent with the radiological findings of ICEP.
PFT results vary from person to person; approximately 50% have obstructive type and 50% have restrictive type of lung defects. DLCO is frequently reduced (6, 7) . In a study investigating the results of long-term PFTs in patients with ICEP, Durieu et al. (16) reported that obstructive defects are common in ICEP and that obstruction might appear even in the absence of any clinical and radiological signs of relapse. Among our patients, 64% showed restrictive type of defects and 18% showed obstructive type of defects on PFTs, while 41% showed reduction in DLCO.
The gold standard for the diagnosis of ICEP is open lung biopsy or tissue eosinophilia confirmed at transbronchial lung biopsy; however, histological confirmation of the disease is not necessary (4) . The diagnosis of ICEP is based on the demonstration of characteristic imaging features, i.e., alveolar eosinophilia and/or peripheral eosinophilia and exclusion of other potential causes. The diagnosis is strongly supported by markedly elevated peripheral blood eosinophilia along with typical clinical radiologic findings. Other potential causes of eosinophilia must be carefully investigated, including the history of drug use, exposure to toxics, and parasitic and fungal infections in particular (4).
Despite spontaneous resolution, dramatic clinical and radiologic improvement is observed by treatment with systemic steroids in ICEP. However, there is no consensus in the literature on the initial dose and duration of treatment, and steroid treatment is usually initiated at a dose of 0.3-1 mg/kg/day (6, 8, 10, 16, 17) . Our patients were initiated on therapy with methylprednisolone at a dose of 0.5 mg/kg/ day, and the dose was rapidly reduced based on the clinical and radiological response. Symptoms improve within the first 2 days, and infiltrates on chest imaging completely disappear in all patients within 1 week without any sequelae (6) (7) (8) 18) . Relapse occurs in 50% of the patients during reduction or discontinuation of the dose. Relapse is more frequent in patients treated for less than 6 months (5, 6, 15, 19) . Prolonged corticosteroid treatment may be required due to frequent relapses in some patients, and the prednisone dose needed to prevent relapse in such cases is often <10 mg (6). In our study, 9 (53%) patients experienced recurrence. Of these, recurrence was after the completion of the steroid treatment in 2 and during the dose reduction of steroids in 7. Six patients were maintained on a low dose of steroids (methylprednisolone, 4-8 mg) due to repeating relapses. Among these patients, 7 (77.7%) had a total IgE level of above 500/IU/mL.
CONCLUSION
Relapses are common in ICEP after the completion of the treatment with corticosteroids or during dose reduction. The close monitoring of patients is recommended for identifying relapse. Furthermore, we believe that a higher total IgE level during diagnosis serves as a predictor of recurrence; therefore, studies with larger series are required to further elucidate it. 
